us cryptocurrencies snippets

Huabei Pharmaceutical Co., Ltd.: Four kinds of drugs under the company are planned to be selected for national centralized drug procurement. Huabei Pharmaceutical announced that the company and its subsidiary Xiantai Company participated in the tenth batch of national centralized drug procurement, and all four varieties are planned to be selected, including penicillin sodium for injection, piperacillin sodium for injection, ampicillin sodium for injection and sulbactam sodium for injection. The price of the drug to be selected this time has decreased compared with the original sales price. In 2023, the sales income of penicillin sodium for injection was 129 million yuan, accounting for 1.28% of the annual operating income. If the bid is confirmed and the purchase and sale contract is signed, the company will fully guarantee the supply according to the demand of the selected area, and promote the increment of related products in the selected area and the development of the off-standard market.Weilai announced that the number of power exchanges had exceeded 60 million times. Weilai issued a document saying that as of 21:06:08 on December 13th, 2024, Weilai had changed power more than 60 million times! Thank you for your support and trust in Weilai.Huangshan Capsule: It is planned to distribute a cash dividend of 0.27 yuan for every 10 shares. Huangshan Capsule announced that the company held the board of directors and the board of supervisors on December 13, 2024, and reviewed and approved the profit distribution plan for the first three quarters of 2024. According to the plan, the company plans to distribute a cash dividend of RMB27 to all shareholders for every 10 shares based on the existing total share capital of 299 million shares, with a total cash dividend of RMB8,075,700. This profit distribution will not send bonus shares, and capital reserve will not be converted into share capital.

Market news: South Korean court issued an arrest warrant to Seoul police chief.Kexing launched the world's first phase III clinical study of bivalent inactivated enterovirus vaccine. On December 13th, the first volunteer was enrolled in the phase III clinical study of bivalent inactivated enterovirus vaccine developed by Beijing Kexing Biological Products Co., Ltd., a subsidiary of Kexing Holding Biotechnology Co., Ltd. (hereinafter referred to as "Kexing"). The vaccine is used to prevent hand, foot and mouth disease caused by enterovirus 71 (EV71) and coxsackie virus 16 (CA16). A multicenter, randomized, double-blind, controlled study design was adopted in this phase III clinical study to evaluate the protective efficacy, safety and immunogenicity of the vaccine in children aged 6-71 months.BYD Lian Yubo: It is estimated that BYD will sell 4.25 million vehicles in the whole year. On December 13th, BYD's chief scientist Lian Yubo said: "Up to now, BYD has sold more than 10 million new energy vehicles. By the end of this month, we can probably achieve the annual sales of 4.25 million vehicles. " He also mentioned: "There are still some challenges in industrial development. For example, the overall anti-risk ability of our industrial chain needs to be improved, and there are still breakthroughs in chips, operating technologies, industrial software and nuclear materials. We still need to strengthen research and achieve complete autonomy and controllability."

Russia's seaborne grain exports in November increased by 39.5% to 4.8 million tons.Daye shares: the proposed acquisition of 100% equity of Al-Kogerte GmbH constitutes a major asset restructuring. Daye shares announced that the company intends to acquire 100% equity of Al-Kogerte GmbH in cash through its wholly-owned subsidiary RUNBO INT PTE.LTD, which constitutes a major asset restructuring of the company.Market News: Austria provides 1,000 euros to Syrian refugees to help them return home.